Jazz Pharmaceuticals CEO Bruce Cozadd's 2018 pay rises 11% to $11M
Jazz Pharmaceuticals reports 2018 executive compensation
By ExecPay News
Published: June 14, 2019
Jazz Pharmaceuticals reported fiscal year 2018 executive compensation information on June 14, 2019.
In 2018, five executives at Jazz Pharmaceuticals received on average a compensation package of $5.4M, a 24% increase compared to previous year.
Average pay of disclosed executives at Jazz Pharmaceuticals
Bruce C. Cozadd, Chief Executive Officer, received $11M in total, which increased by 11% compared to 2017. 45% of Cozadd's compensation, or $5.2M, was in stock awards. Cozadd also received $980K in non-equity incentive plan, $4.3M in option awards, $979K in salary, as well as $13K in other compensation.
For fiscal year 2018, the median employee pay was $216,797 at Jazz Pharmaceuticals. Therefore, the ratio of Bruce C. Cozadd's pay to the median employee pay was 53 to one.
Daniel N. Swisher, Jr, Chief Operating Officer, received a compensation package of $5.8M. 44% of the compensation package, or $2.5M, was in stock awards.
Suzanne Sawochka Hooper, Former Executive Vice President and GC, earned $3.4M in 2018, a 2% increase compared to previous year.
Matthew P. Young, Chief Financial Officer, received $3.4M in 2018, which increases by 2% compared to 2017.
Michael P. Miller, Executive Vice President U.S Commercial, earned $2.9M in 2018, which is about the same as previous year.
Related executives
Bruce Cozadd
Jazz Pharmaceuticals
Chief Executive Officer
Daniel Swisher
Jazz Pharmaceuticals
President
Matthew Young
Jazz Pharmaceuticals
Chief Financial Officer
Suzanne Hooper
Jazz Pharmaceuticals
Former Executive Vice President and GC
Michael Miller
Jazz Pharmaceuticals
Executive Vice President U.S Commercial
You may also like
Source: SEC filing on June 14, 2019.